

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/196,673		
		Filing Date	November 20, 1998		
		First Named Inventor	McCafferty		
		Group Art Unit	1627		
		Examiner Name	P. Ponnaluri		
Sheet	1	of	3	Attorney Docket Number	213839-00003

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US 6,331,415	12-18-2001	Cabilly et al.	considered in PTO 1449

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner Signature	P. Ponnaluri	Date Considered	3/13/02
-----------------------	--------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO Patent Documents as www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/196,673
		Filing Date	November 20, 1998
		First Named Inventor	McCafferty
		Group Art Unit	1627
Examiner Name	P. Ponnaluri		
Attorney Docket Number	213839-00003		
Sheet	2	of	3

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
pp	C1	Barbas and Lerner "Combinatorial Immunoglobulin Libraries on the surface of phage (Phabs): rapid selection of anti-specific fabs." Methods: a companion to methods in Enzymology Vol. 2 (2): 119-124 (1991).	
	C2	Interlocutory Decision in Opposition Proceedings to the European Patent EP-B-0589877 dated April 15, 2002 (reference number SMW/CP9503921)	
	C3	Notice of Appeal to the European Patent EP-B-0589877 from Dyax Corp., filed June 17, 2002	
	C4	Communication from EPO on Notice of Appeal filed by Dyax, issued October 21, 2002	
	C5	Notice of Appeal to the European Patent EP-B-0589877 from BioInvent Therapeutic AB, filed June 14, 2002	
	C6	Appeal No. T0639/02-334 from BioInvent Therapeutic AB to the European Patent EP-B-0589877, filed August 22, 2002	
	C7	Notice of Appeal to the European Patent EP-B-0589877 from MorphoSys AG filed June 20 2002 and Grounds of the Appeal filed August 22, 2002	
	C8	Notice of Appeal filed June 24, 2002 and Grounds of Appeal filed August 22, 2002 from Cambridge Antibody Technology Limited against the Decision of the Opposition Division	
	C9	Notice of Opposition to the European Patent EP-B-0589877 from BioInvent International AB, filed October 24 2002	
	C10	Document D80 in Appeal No. T0639/02-334: HHS' Freedom of Information Act (FOIA) regulations: table of contents, 5.1, 5.2, 5.3, 5.5, 5.21, 5.22, 5.24, 5.31, 5.32, 5.33, 5.34, 5.35, 5.51, 5.61 and 5.65	
	C11	Document D81 in Appeal No. T0639/02-334: Smith Declaration	
	C12	Document D82 in Appeal No. T0639/02-334: Copy of Grant Application GM 41478 and renewal applications supplied by the DHH	
	C13	Document D83 in Appeal No. T0639/02-334: Letter dated 26 August 1999 from Cambridge Antibody Technology Ltd in opposition proceedings against EP 0 527 839	
	C14	Document D85 in Appeal No. T0639/02-334: Proprietor's letter of 12 November 1997 and amended claims	

PP	C15	Document D86 in Appeal No. T0639/02-334: EP 0774 511 A1	
	C16	Document D87 in Appeal No. T0639/02-334: Proprietor's letter of 15 November 2000	
	C17	Document D88 in Appeal No. T0639/02-334: Grounds of Appeal dated 22 August 2002 from present opponent in opposition proceedings against EP 0589 877	
	C18	Document D89 in Appeal No. T0639/02-334: OD's Written Interlocutory Decision in opposition proceedings against EP 0 589 877	
	C19	Document D90 in Appeal No. T0639/02-334: Marvin & Hohn (1969). Bacteriological Rev 33(2), 172-209	
	C20	Document D91 in Appeal No. T0639/02-334: Better et al. (1988). Science 240, 1041-1043	
	C21	Document D92 in Appeal No. T0639/02-334: Sambrook & Russel (2001). Molecular cloning: a laboratory manual 3rd Eddition, Cold Spring Harbor Press; particular pages 18.115 to 18.122 "Filamentous phage display"	
	C22	Notice of Opposition to the European Patent EP-B-0589877 from Crucell Holland B.V, filed October 30 2002	
	C23	Document D13: Communication of the European Office of 28 June 2001	
	C24	Document D17: Vieira and Messing (1987), Methods Enzymol. 153, 3-11	
	C25	Document D27: Details of Smith Grant application and second and third year renewals thereof as provided by the DHHS in response to a Freedom to Information Act (FOIA) request	
	C26	Notice of Opposition to the European Patent EP-B-0589877 from Dyax Corp.	
	C27	Document D1: EPO register print-out for the patent application with file history information	
	C28	Document D3: Claims filed with the divisional application	
	C29	Document D7: Pluckthun and Skerra, "Expression of functional antibody Fv and Fab fragments in Escherichia coli," Methods in Enzymology, Vol. 178 (1989), pages 497-515	
	C30	Document D8: Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodology for displaying antibody (Fab) heavy and light chains," Nucleic Acids Research, Vol 19, No. 15 (1991), pages 4133-4137.	
	C31	Notice of Opposition to the European Patent EP-B-0589877 from MorphoSys, filed October 30 2002	
✓	C32	Document D1: Genentech, US Patent Application 07/621,667, priority document to EP 92902109.5	

Examiner Signature	P. Ponnaluri	Date Considered	3/18/03
--------------------	--------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.